Results(4658)
Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie (Embryotox), Charité-Universitätsmedizin, Berlin
Germany
First published:
22/05/2026
Institution
Educational Institution
ENCePP partner
Integrated Primary Care Information (IPCI)
Primary care medical records
Netherlands
First published:
22/05/2026
Data source
Human
Record completeness: 83%
European Registries for Rare Endocrine and Bone Conditions
Disease registry
Austria
Belgium
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Israel
Italy
Latvia
Lithuania
Luxembourg
Netherlands
Norway
Poland
Portugal
Romania
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Türkiye
Ukraine
United Kingdom
United Kingdom (Northern Ireland)
First published:
22/05/2026
Data source
Human
Record completeness: 79%
Hippocrates Research S.r.l.
Italy
Switzerland
First published:
22/05/2026
Institution
Non-Pharmaceutical company
ENCePP partner
TAK-620-4007: Retrospective Chart Review of Safety Outcomes Associated With Use of Maribavir in Patients With Post-transplant Refractory Cytomegalovirus (CMV) Infection and Comorbid Severe Chronic Kidney Disease (CKD) or Comorbid End-stage Renal Disease (ESRD), Including Patients on Peritoneal Dialysis or Hemodialysis
Austria
Belgium
Denmark
Estonia
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000006
First published:
22/05/2026
Study
Ongoing
ImPact of comoRbidity In Severe asthMa patients (PRISM)
Argentina
Australia
Bulgaria
Canada
Colombia
Denmark
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Poland
Portugal
Saudi Arabia
Spain
Taiwan
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS44024
First published:
22/05/2026
Study
Finalised
Belzutifan special drug use results survey in von Hippel-Lindau (VHL) disease-associated tumors: a post-authorization safety study (PASS) (MK-6482-046)
Japan
EU PAS number:
EUPAS1000000881
First published:
22/05/2026
Study
Planned
Belzutifan special drug use results survey in radically unresectable or metastatic renal cell carcinoma: a postauthorization safety study (PASS) (MK-6482-045)
Japan
EU PAS number:
EUPAS1000000880
First published:
22/05/2026
Study
Ongoing
VAC4EU Postauthorisation Safety Study of BIMERVAX® Vaccine in Europe
Spain
EU PAS number:
EUPAS1000000321
First published:
22/05/2026
Study
Planned
Incidence of Thyroid Neoplasm and Pancreatic Cancer in Type 2 Diabetes Mellitus Patients who Initiate Once Weekly Exenatide Compared with Other Antihyperglycemic Drugs
United Kingdom
EU PAS number:
EUPAS13904
First published:
22/05/2026
Study
Finalised
A prospective study to evaluate the safety, effectiveness and impact of the RTS, S/AS01E vaccine in young children in sub-Saharan Africa (EPI-MALARIA-003 VS AME) (115056)
Ghana
Kenya
Malawi
EU PAS number:
EUPAS28541
First published:
22/05/2026
Study
Finalised
TARGET EU: Comparative effectiveness and safety studies using the target trial emulation and estimand frameworks
Belgium
Denmark
Finland
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000539
First published:
22/05/2026
Study
Planned
TARGET-EU: Comparison of single-device vilanterol/fluticasone furoate with other single-device inhaled corticosteroid and long-acting beta agonist combinations in the risk of pneumonia in adolescents with asthma
Belgium
Finland
Netherlands
United Kingdom
EU PAS number:
EUPAS1000000989
First published:
22/05/2026
Study
Planned
CAB LA PrEP Cohort: Prospective Cohort Study to Assess Adherence and Effectiveness of, and Monitor for Hepatotoxicity and Resistance to, Cabotegravir for Pre-Exposure Prophylaxis in Europe (221935)
Belgium
France
Ireland
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000299
First published:
22/05/2026
Study
Ongoing
Pregnancy and Neonatal Outcomes following Prenatal Exposure to Cabotegravir: Data from The Antiretroviral Pregnancy Registry (APR) (215325)
Canada
Czechia
France
Germany
Italy
Netherlands
Portugal
Russian Federation
Spain
United Kingdom
EU PAS number:
EUPAS45685
First published:
22/05/2026
Study
Ongoing
A Real-world, Prospective, Observational Study of Prolia® (20180401)
China
EU PAS number:
EUPAS37579
First published:
22/05/2026
Study
Ongoing
TARGET-EU: Risk of adverse birth and neurodevelopmental outcomes in children born alive to fathers exposed to valproate versus levetiracetam for generalised epilepsy
Netherlands
Spain
EU PAS number:
EUPAS1000000999
First published:
22/05/2026
Study
Planned
DARWIN EU® - Drug utilisation study of intramuscular depot olanzapine
Croatia
Denmark
Germany
Hungary
Sweden
EU PAS number:
EUPAS1000000980
First published:
22/05/2026
Study
Ongoing
Clinical Practice Research Datalink (CPRD) GOLD
Primary care medical records
United Kingdom
First published:
20/05/2026
Data source
Human
Record completeness: 97%
Effectiveness of ROTATEQ® when administered with intervals greater than 10 weeks between doses in Chinese children: an observational study of V260-077 study participants with longer dosing interval (V260-080)
China
EU PAS number:
EUPAS1000000730
First published:
20/05/2026
Study
Ongoing
Observational study to assess effectiveness of ROTATEQ® against acute gastroenteritis (AGE) due to rotavirus (regardless of type) and by type in China
China
EU PAS number:
EUPAS1000000734
First published:
20/05/2026
Study
Ongoing
TARGET-EU: Tolvaptan and risk associated to hepatotoxicity in autosomal dominant polycystic kidney disease
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000001005
First published:
20/05/2026
Study
Ongoing
id.DRIVE pilot study to assess the detection of RSV, hMPV and PIV when using multi-specimen collection compared to a single nasopharyngeal swab
Spain
EU PAS number:
EUPAS1000000780
First published:
20/05/2026
Study
Planned
Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study
Austria
France
Germany
Israel
Italy
Netherlands
Portugal
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS45972
First published:
20/05/2026
Study
Ongoing
TARGET-EU: Effectiveness of nirsevimab for RSV-lower respiratory tract infection hospitalization in infants ≤12 months of age
Italy
EU PAS number:
EUPAS1000000993
First published:
19/05/2026
Study
Planned
Research Repository @Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Hospital discharge records
Hospital inpatient records
Hospital outpatient visit records
Other
Italy
First published:
19/05/2026
Data source
Human
Record completeness: 91%
116682 - An epidemiology study to assess Plasmodium falciparum parasite prevalence and malaria control measures in catchment areas of two studies pre- and post RTS,S/AS01E introduction (EPI MAL-002 and EPI-MAL-003) to assess, in field conditions, vaccine benefit:risk in children in sub Saharan Africa. (EPI-MALARIA-005 BOD AME)
Burkina Faso
Ghana
Kenya
Malawi
Senegal
Tanzania, United Republic of
EU PAS number:
EUPAS43920
First published:
19/05/2026
Study
Finalised
A regulatory requirement non-interventional study to monitor the safety and effectiveness of Jardiance® (empagliflozin, 10mg) in Korean patients with chronic heart failure (NYHA class II-IV)
Korea, Republic of
EU PAS number:
EUPAS44641
First published:
19/05/2026
Study
Finalised
Prospective Observational Study on the Safety and Effectiveness of Imdelltra (tarlatamab) 20230176
Korea, Republic of
EU PAS number:
EUPAS1000000778
First published:
19/05/2026
Study
Planned
An Active Surveillance, Post Authorization Safety Study (PASS) of Serious Infection, Malignancy, Cardiovascular (CV) and Other Safety Events of Interest among Patients Treated with Tofacitinib for Moderately to Severely Active Rheumatoid Arthritis (RA) within the German Registry Rheumatoide Arthritis: Beobachtung der Biologika Therapie (RABBIT) (Safety of tofacitinib in RABBIT)
Germany
EU PAS number:
EUPAS31164
First published:
19/05/2026
Study
Ongoing
A Worldwide Pregnancy Safety Study to Assess Maternal, Foetal, and Infant Outcomes Following Exposure to Efgartigimod alfa during Pregnancy and/or Breastfeeding
Germany
Italy
Spain
United States
EU PAS number:
EUPAS1000000005
First published:
19/05/2026
Study
Ongoing
Real-world comparative effectiveness of tofacitinib, tumour necrosis factor inhibitors, and interleukin 17 inhibitors among patients with axial spondylarthritis and psoriatic arthritis
United States
EU PAS number:
EUPAS1000000226
First published:
19/05/2026
Study
Ongoing
MEMO Research, University of Dundee
United Kingdom (Northern Ireland)
First published:
19/05/2026
Institution
Educational Institution
Not-for-profit
ENCePP partner
Unidade Local de Saúde São João (ULSSJ)
Portugal
First published:
19/05/2026
Institution
Hospital/Clinic/Other health care facility
ENCePP partner
European Network of Teratology Information Services (ENTIS)
Austria
Czechia
Finland
France
Germany
Greece
Ireland
Italy
Netherlands
Spain
Switzerland
United Kingdom
First published:
19/05/2026
Network
ENCePP partner
IQVIA Disease Analyzer Germany
Primary care medical records
Germany
First published:
18/05/2026
Data source
Human
Record completeness: 93%
IQVIA Longitudinal Patient Data - Belgium
Primary care medical records
Belgium
First published:
18/05/2026
Data source
Human
Record completeness: 97%
HARMONY Alliance Foundation Platform
Cancer registry
Disease registry
Other
Registration with healthcare system
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
Colombia
Croatia
Cuba
Czechia
Denmark
Egypt
France
Germany
Greece
Hungary
Italy
Kuwait
Moldova, Republic of
Netherlands
Poland
Qatar
Serbia
Singapore
Slovakia
Spain
Sweden
Switzerland
Taiwan
United Kingdom
United Kingdom (Northern Ireland)
Uruguay
First published:
18/05/2026
Data source
Human
Record completeness: 87%
Hospital District of Helsinki and Uusimaa patient cohort (FinOMOP)
Other
Finland
First published:
18/05/2026
Data source
Human
Record completeness: 97%
DARWIN EU® - Alzheimer’s Disease: Incidence, Prevalence, and Individuals' Characteristics
Croatia
Denmark
Germany
Netherlands
United Kingdom
EU PAS number:
EUPAS1000000826
First published:
18/05/2026
Study
Finalised
Compare data sources
Compare data sources